| scholarly article | Q13442814 |
| P50 | author | Joseph DeSimone | Q6282541 |
| Saurabh Wadhwa | Q81499662 | ||
| J Christopher Luft | Q125314479 | ||
| P2093 | author name string | Rihe Liu | |
| Matthew C Parrott | |||
| Dongwook Kim | |||
| Russell J Mumper | |||
| S Rahima Benhabbour | |||
| Anekant Jain | |||
| P2860 | cites work | Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody | Q40502849 |
| Influence of multivalent nitrilotriacetic acid lipid-ligand affinity on the circulation half-life in mice of a liposome-attached His6-protein | Q40672864 | ||
| Tris-nitrilotriacetic acids of subnanomolar affinity toward hexahistidine tagged molecules | Q41238943 | ||
| Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy | Q41617040 | ||
| Gadolinium-loaded nanoparticles engineered from microemulsion templates | Q44003573 | ||
| Metallochelating liposomes with associated lipophilised norAbuMDP as biocompatible platform for construction of vaccines with recombinant His-tagged antigens: preparation, structural study and immune response towards rHsp90. | Q44366080 | ||
| Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation | Q44907727 | ||
| Preparation and characterization of nickel nanoparticles for binding to his-tag proteins and antigens | Q45098418 | ||
| Facile synthesis of multivalent nitrilotriacetic acid (NTA) and NTA conjugates for analytical and drug delivery applications | Q46251950 | ||
| FDA drug approval summary: erlotinib (Tarceva) tablets | Q46633705 | ||
| The novel chelator lipid 3(nitrilotriacetic acid)-ditetradecylamine (NTA(3)-DTDA) promotes stable binding of His-tagged proteins to liposomal membranes: potent anti-tumor responses induced by simultaneously targeting antigen, cytokine and costimulat | Q46753543 | ||
| New, simple flow cytometry technique to discriminate between internalized and membrane-bound particles in phagocytosis | Q69499549 | ||
| Segregation of receptor and ligand regulates activation of epithelial growth factor receptor | Q24298164 | ||
| Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib | Q28263625 | ||
| Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells | Q28299546 | ||
| Selection and characterization of HER2/neu-binding affibody ligands | Q33203999 | ||
| Tumor imaging using a picomolar affinity HER2 binding affibody molecule | Q33240101 | ||
| Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy | Q33279445 | ||
| Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule | Q33315521 | ||
| Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold | Q33330736 | ||
| Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice | Q33483984 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain | Q34435244 | ||
| Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting | Q34687526 | ||
| Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). | Q35104928 | ||
| Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer | Q35177848 | ||
| Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging | Q36100348 | ||
| Dual-mode fluorophore-doped nickel nitrilotriacetic acid-modified silica nanoparticles combine histidine-tagged protein purification with site-specific fluorophore labeling | Q36868004 | ||
| Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. | Q37378180 | ||
| Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. | Q37595605 | ||
| Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization | Q39900986 | ||
| Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells. | Q40177371 | ||
| Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting | Q40262046 | ||
| Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. | Q40304728 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanoparticle | Q61231 |
| P304 | page(s) | 63-71 | |
| P577 | publication date | 2011-10-20 | |
| P1433 | published in | Journal of Controlled Release | Q6295046 |
| P1476 | title | In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain | |
| P478 | volume | 158 |
| Q36360764 | A critical review of lipid-based nanoparticles for taxane delivery |
| Q37591930 | GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation |
| Q34389242 | Heptameric targeting ligands against EGFR and HER2 with high stability and avidity |
| Q51068477 | Rapid microwave-assisted synthesis of sub-30nm lipid nanoparticles. |
| Q30436623 | Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice. |
| Q64096692 | Rationally designed carbohydrate-occluded epitopes elicit HIV-1 Env-specific antibodies |
| Q47190264 | Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review |
| Q38691793 | Targeted PRINT Hydrogels: The Role of Nanoparticle Size and Ligand Density on Cell Association, Biodistribution, and Tumor Accumulation |
| Q26995399 | Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges |
| Q38981743 | Trends on polymer- and lipid-based nanostructures for parenteral drug delivery to tumors |
Search more.